SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION																
				Washington, D.C. 20549										0	MB APPRO	/AL
Section 16. Form 4 or Form 5 obligations may continue. See					NT OF CHANGES IN BENEFICIAL OWNE ad pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940								Estin		umber:	3235-0287 1 0.5
1. Name and Address of Reporting Person [*] Goldberg Mark Alan						2. Issuer Name and Ticker or Trading Symbol ImmunoGen, Inc. [IMGN]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner			
(Last) (First) (Middle) C/O IMMUNOGEN, INC.						3. Date of Earliest Transaction (Month/Day/Year) 06/16/2021							Officer (give title Other (specify below) below)			
830 WINTER STREET					4. 11	4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable Line)			
(Street) WALTH	(Street) WALTHAM MA 02451												X Form filed by One Reporting Person Form filed by More than One Reporting Person			
(City)	(S	tate)	(Zip)													
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned															
1. Title of Security (Instr. 3) 2. Trans Date (Month/l)					Execution Date			Code (In:	ion Dispose	ties Acquired (A) or d Of (D) (Instr. 3, 4 and		Benefici	es F ally (Following (Form: Direct	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
								Code \	Amount	(A) c (D)	Price	Transac (Instr. 3	tion(s)		(iiisti: 4)	
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)															
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security		3. Transaction Date (Month/Day/Year)	3A. Deemed Execution I if any (Month/Day	i 4 Date, 1	4. Transaction Code (Instr 8)		5. Number of		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Deferred Share Unit	\$0 ⁽¹⁾	06/16/2021			A		15,000		(3)(2)	(2)	Common Stock ⁽²⁾	15,000	\$0 ⁽¹⁾	124,876	D	
Stock Option (right to buy)	\$6.77	06/16/2021			Α		44,000	*	(4)	06/16/2031	Common	44,000	\$6.77	44,000	D	

Explanation of Responses:

1. The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis.

2. The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors.

3. The deferred share units vest quarterly on each of 9/1/21, 12/1/21, 3/1/22, and 6/1/22, contingent upon the individual remaining a director as of each vesting date.

4. Exercisable as to 11,000 shares on each of 9/1/21, 12/1/21, 3/1/22, and 6/1/22, contingent upon the individual remaining a director as of each vesting date.

<u>/s/ Joseph J. Kenny, attorney in</u> <u>fact</u> <u>06/17/2021</u>

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.